Two Sigma Advisers LP Sells 11,400 Shares of Fresenius Medical Care AG (NYSE:FMS)

Two Sigma Advisers LP reduced its position in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 19.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 48,600 shares of the company's stock after selling 11,400 shares during the quarter. Two Sigma Advisers LP's holdings in Fresenius Medical Care were worth $1,100,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the business. Smartleaf Asset Management LLC increased its holdings in Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock valued at $28,000 after purchasing an additional 806 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Fresenius Medical Care by 234.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock valued at $71,000 after acquiring an additional 2,208 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Fresenius Medical Care by 80.5% during the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock worth $102,000 after purchasing an additional 2,012 shares in the last quarter. Venturi Wealth Management LLC grew its stake in Fresenius Medical Care by 8.4% in the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock valued at $129,000 after acquiring an additional 441 shares during the period. Finally, Assetmark Inc. grew its position in shares of Fresenius Medical Care by 196.3% in the 4th quarter. Assetmark Inc. now owns 7,210 shares of the company's stock valued at $163,000 after purchasing an additional 4,777 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Trading Down 0.3%

Shares of Fresenius Medical Care stock traded down $0.09 on Wednesday, reaching $28.24. 245,680 shares of the company's stock were exchanged, compared to its average volume of 332,562. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $30.46. The company has a market capitalization of $16.57 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The firm's 50-day moving average is $26.20 and its two-hundred day moving average is $24.41. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The firm had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. Sell-side analysts predict that Fresenius Medical Care AG will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be given a $0.7871 dividend. This is a positive change from Fresenius Medical Care's previous annual dividend of $0.44. This represents a dividend yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. Fresenius Medical Care's dividend payout ratio (DPR) is currently 49.11%.

Wall Street Analyst Weigh In

FMS has been the topic of a number of recent research reports. Truist Financial lifted their target price on Fresenius Medical Care from $25.00 to $30.00 and gave the company a "hold" rating in a research report on Monday, May 12th. Wall Street Zen began coverage on Fresenius Medical Care in a research report on Tuesday, May 20th. They set a "strong-buy" rating on the stock. Finally, Morgan Stanley reissued an "underweight" rating on shares of Fresenius Medical Care in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $27.80.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.